Logo image of IOVA

IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Fundamental Analysis

NASDAQ:IOVA - Nasdaq - US4622601007 - Common Stock - Currency: USD

1.87  -0.06 (-3.11%)

After market: 1.87 0 (0%)

Fundamental Rating

2

Overall IOVA gets a fundamental rating of 2 out of 10. We evaluated IOVA against 557 industry peers in the Biotechnology industry. While IOVA seems to be doing ok healthwise, there are quite some concerns on its profitability. IOVA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IOVA has reported negative net income.
IOVA had a negative operating cash flow in the past year.
In the past 5 years IOVA always reported negative net income.
In the past 5 years IOVA always reported negative operating cash flow.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M

1.2 Ratios

IOVA has a Return On Assets (-38.83%) which is comparable to the rest of the industry.
IOVA's Return On Equity of -48.88% is fine compared to the rest of the industry. IOVA outperforms 65.71% of its industry peers.
Industry RankSector Rank
ROA -38.83%
ROE -48.88%
ROIC N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

IOVA's Gross Margin of 21.72% is fine compared to the rest of the industry. IOVA outperforms 73.25% of its industry peers.
IOVA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 21.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K

More info and screens

4

2. Health

2.1 Basic Checks

IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IOVA has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, IOVA has more shares outstanding
Compared to 1 year ago, IOVA has an improved debt to assets ratio.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

IOVA has an Altman-Z score of -2.31. This is a bad value and indicates that IOVA is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -2.31, IOVA perfoms like the industry average, outperforming 50.45% of the companies in the same industry.
IOVA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
IOVA's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. IOVA outperforms 47.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.31
ROIC/WACCN/A
WACC9.79%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

IOVA has a Current Ratio of 4.18. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
IOVA has a Current ratio of 4.18. This is comparable to the rest of the industry: IOVA outperforms 47.40% of its industry peers.
A Quick Ratio of 3.64 indicates that IOVA has no problem at all paying its short term obligations.
IOVA's Quick ratio of 3.64 is in line compared to the rest of the industry. IOVA outperforms 44.34% of its industry peers.
Industry RankSector Rank
Current Ratio 4.18
Quick Ratio 3.64
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

IOVA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.11%, which is quite impressive.
IOVA shows a strong growth in Revenue. In the last year, the Revenue has grown by 11052.54%.
EPS 1Y (TTM)31.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
Revenue 1Y (TTM)11052.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6798.46%

3.2 Future

Based on estimates for the next years, IOVA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.06% on average per year.
Based on estimates for the next years, IOVA will show a very strong growth in Revenue. The Revenue will grow by 46.08% on average per year.
EPS Next Y11.13%
EPS Next 2Y18.79%
EPS Next 3Y22.35%
EPS Next 5Y19.06%
Revenue Next Year84.47%
Revenue Next 2Y77.06%
Revenue Next 3Y64.93%
Revenue Next 5Y46.08%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IOVA. In the last year negative earnings were reported.
Also next year IOVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as IOVA's earnings are expected to grow with 22.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.79%
EPS Next 3Y22.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IOVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (7/11/2025, 8:24:48 PM)

After market: 1.87 0 (0%)

1.87

-0.06 (-3.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-07 2025-08-07/amc
Inst Owners70.12%
Inst Owner Change0%
Ins Owners0.35%
Ins Owner Change22.63%
Market Cap624.45M
Analysts77.78
Price Target10.91 (483.42%)
Short Float %30.81%
Short Ratio6.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.44%
Min EPS beat(2)-47.45%
Max EPS beat(2)4.58%
EPS beat(4)3
Avg EPS beat(4)-7.24%
Min EPS beat(4)-47.45%
Max EPS beat(4)8.26%
EPS beat(8)6
Avg EPS beat(8)1.78%
EPS beat(12)9
Avg EPS beat(12)4.27%
EPS beat(16)10
Avg EPS beat(16)2.98%
Revenue beat(2)0
Avg Revenue beat(2)-20.51%
Min Revenue beat(2)-40.82%
Max Revenue beat(2)-0.2%
Revenue beat(4)2
Avg Revenue beat(4)-2.57%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)24.03%
Revenue beat(8)2
Avg Revenue beat(8)-40.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-44.22%
PT rev (3m)-48.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-32.35%
EPS NY rev (1m)-9.3%
EPS NY rev (3m)-41.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-32.31%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)-33.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.94
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-1.24
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.64
BVpS2.3
TBVpS1.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.83%
ROE -48.88%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 21.72%
FCFM N/A
ROA(3y)-52.47%
ROA(5y)-47.04%
ROE(3y)-69.19%
ROE(5y)-60.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.84%
Cap/Sales 6.16%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.18
Quick Ratio 3.64
Altman-Z -2.31
F-Score5
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)118.96%
Cap/Depr(5y)1133.86%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%14.29%
EPS Next Y11.13%
EPS Next 2Y18.79%
EPS Next 3Y22.35%
EPS Next 5Y19.06%
Revenue 1Y (TTM)11052.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%6798.46%
Revenue Next Year84.47%
Revenue Next 2Y77.06%
Revenue Next 3Y64.93%
Revenue Next 5Y46.08%
EBIT growth 1Y16.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.71%
EBIT Next 3Y28.38%
EBIT Next 5YN/A
FCF growth 1Y-4.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.9%
OCF growth 3YN/A
OCF growth 5YN/A